PAPER Anand P, Singh B

A review on cholinesterase inhibitors for Alzheimer's disease.

Arch Pharm Res. 2013 Apr;36(4):375-99. PubMed: 23435942

PAPER Paul S, Hwang JK, Kim HY, Jeon WK, Chung C, Han JS

Multiple biological properties of macelignan and its pharmacological implications.

Arch Pharm Res. 2013 Mar;36(3):264-72. PubMed: 23435944

PAPER Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyás B, Borg J, Boellaard R, Al-Tawil N, Eriksdotter M, Zimmermann T, Schultze-Mosgau M, Thiele A, Hoffmann A, Lammertsma AA, Halldin C

In vivo imaging of the 18-kDa translocator protein (TSPO) with [(18)F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):921-31. PubMed: 23436070

PAPER Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A

The current and projected economic burden of Parkinson's disease in the United States.

Mov Disord. 2013 Mar;28(3):311-8. PubMed: 23436720

PAPER Zhang J, Li P, Wang Y, Liu J, Zhang Z, Cheng W

Ameliorative effects of a combination of baicalin, jasminoidin and cholic acid on ibotenic acid-induced dementia model in rats.

PLoS One. 2013;8(2):e56658. PubMed: 23437202

PAPER Sonde L, Johnell K

Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.

PLoS One. 2013;8(2):e57161. PubMed: 23437334

PAPER Brandt J, Sullivan C, Burrell LE, Rogerson M, Anderson A

Internet-based screening for dementia risk.

PLoS One. 2013;8(2):e57476. PubMed: 23437393

PAPER Ma SL, Lam LC

Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease.

Clin Psychopharmacol Neurosci. 2011 Aug;9(2):54-66. PubMed: 23429712

PAPER Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, Orrell RW, Malaspina A, Rowe J, Brown J, Hodges J, Sidle K, Polke JM, Houlden H, Schott JM, Fox NC, Rossor MN, Tabrizi SJ, Isaacs AM, Hardy J, Warren JD, Collinge J, Mead S

Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.

Am J Hum Genet. 2013 Mar 7;92(3):345-53. Epub 2013 Feb 21 PubMed: 23434116

PAPER Tanaka H, Shimazawa M, Takata M, Kaneko H, Tsuruma K, Ikeda T, Warita H, Aoki M, Yamada M, Takahashi H, Hozumi I, Minatsu H, Inuzuka T, Hara H

ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis.

J Neurol. 2013 Feb 23; PubMed: 23436019

PAPER Degnan AJ, Levy LM

Neuroimaging of Rapidly Progressive Dementias, Part 1: Neurodegenerative Etiologies.

AJNR Am J Neuroradiol. 2013 Mar 21; PubMed: 23436051

PAPER Barkhof F, Daams M, Scheltens P, Brashear HR, Arrighi HM, Bechten A, Morris K, McGovern M, Wattjes MP

An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion.

AJNR Am J Neuroradiol. 2013 Feb 22; PubMed: 23436056

PAPER Robakis NK

Cell Signaling Abnormalities May Drive Neurodegeneration in Familial Alzheimer Disease.

Neurochem Res. 2013 Feb 23; PubMed: 23436150

PAPER Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR,

Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study.

J Clin Pharmacol. 2013 Feb;53(2):234-9. PubMed: 23436269

Luc Buee on Exploring Genome Fragmentation in Neurodegeneration

COMMENT We all agree that DNA damage increases with aging. Many proteins described in neurodegenerative disorders may be involved in this process. A key one is once again forgotten: tau. Luc.Buee 0 Nuclear tau, a key player in neuronal DNA protection.